Bone Therapeutics SA: The preliminary documents for the Annual General Shareholder Meeting on 26 May 2017 have been made avai...
April 26 2017 - 1:00AM
The preliminary documents for the Annual General Shareholder
Meeting on 26 May 2017 have been made available
Gosselies, Belgium, 26 April
2017, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and
Paris: BOTHE), the bone cell therapy company addressing high unmet
medical needs in orthopaedics and bone diseases, informs its
shareholders that the Annual General Meeting will be held on 26 May
2017 at 4pm at 37 Rue Auguste Piccard, 6041 Gosselies, Belgium.
The notice for the meeting,
including the agenda of the day as well as the motions to vote,
have been published in the Belgian Official Gazette and L'Echo on
26 April 2017.
The documents and preliminary
information concerning this meeting are being made available to the
shareholders and can be consulted on the website of the Company:
www.bonetherapeutics.com, under the section Investors /
Shareholders meeting, in compliance with the applicable law and
regulations.
It is also possible to receive the
documents without charge upon simple request by email to
valerie.roels@bonetherapeutics.com or by telephone on +32 (0)2
529 59 90. Finally, the documents are available at the Company's
headquarters: 37 Rue Auguste Piccard, 6041 Gosselies, Belgium.
About Bone Therapeutics
Bone Therapeutics is a leading
cell therapy company addressing high unmet needs in orthopaedics
and bone diseases. Based in Gosselies, Belgium, the Company has a
broad, diversified portfolio of bone cell therapy products in
clinical development across a number of disease areas targeting
markets with large unmet medical needs and limited
innovation.
Our technology is based on a
unique, proprietary approach to bone regeneration which turns
undifferentiated stem cells into "osteoblastic", or bone-forming
cells. These cells can be administered via a minimally invasive
procedure, avoiding the need for invasive surgery.
Our primary clinical focus is
ALLOB®, an
allogeneic "off-the-shelf" cell therapy product derived from stem
cells of healthy donors, which is in Phase II studies for the
treatment of delayed-union fractures and spinal fusion. The Company
also has an autologous bone cell therapy product, PREOB®, obtained
from patient's own bone marrow and currently in Phase III
development for osteonecrosis and non-union fractures.
Bone Therapeutics' cell therapy
products are manufactured to the highest GMP standards and are
protected by a rich IP estate covering 9 patent families. Further
information is available at: www.bonetherapeutics.com.
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company or, as
appropriate, the Company directors' current expectations and
projections about future events. By their nature, forward-looking
statements involve a number of risks, uncertainties and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the Company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person's officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Contacts
Bone Therapeutics
SA
Thomas Lienard, Chief Executive
Officer
Wim Goemaere, Chief Financial Officer
Tel: +32 (0)2 529 59 90
investorrelations@bonetherapeutics.com
or
For Belgium and International Media
Enquiries:
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson and Hendrik Thys
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com
or
For French Media and Investor
Enquiries:
NewCap Investor Relations & Financial
Communications
Pierre Laurent, Louis-Victor Delouvrier and Nicolas
Merigeau
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Bone Therapeutics SA via Globenewswire